caption
stringlengths 0
3.92k
| molecule
stringlengths 1
914
| properties
sequencelengths 1
113
| additional_data
dict |
|---|---|---|---|
The molecule has Mild, ester odor. Dicrotophos emits toxic fumes of phosphorus and nitrogen oxides when heated to decomposition. | COP(=O)(OC)OC(C)=CC(=O)N(C)C | [
"Odor_evaluation",
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, membrane stabilizer, fat storage, and nutrient, impacts metabolic syndrome, and is thyroxine treatment. The molecule is a energy storage and energy source, and it impacts atherosclerosis. It has an effect on cancer, and impacts obesity, pancreatitis, and cardiovascular disease. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"inflammatory",
"Membrane stabilizer",
"Fat storage",
"Metabolic syndrome",
"nutrient",
"Thyroxine treatment",
"Energy storage",
"Energy source",
"Atherosclerosis",
"Obesity",
"Pancreatitis",
"Cancer",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, nutrient, and inflammatory that has an effect on cancer and impacts both pancreatitis and metabolic syndrome. The molecule is a energy storage that impacts both atherosclerosis and cardiovascular disease. The molecule is a fat storage and a membrane stabilizer, impacting both thyroxine treatment and obesity. | CC(C)CCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Cancer",
"Energy source",
"nutrient",
"Pancreatitis",
"inflammatory",
"Metabolic syndrome",
"Energy storage",
"Atherosclerosis",
"Cardiovascular disease",
"Thyroxine treatment",
"Obesity",
"Fat storage",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hormone, emulsifier, energy source and belongs to the pharmaceutical class of molecules. The molecule is a energy storage, membrane stabilizer, signalling molecule, surfactant. | Oc1cc2c(cc1O)CNCC2 | [
"hormone",
"Pharmaceutical",
"Emulsifier",
"Energy source",
"Energy storage",
"Membrane stabilizer",
"signalling molecule",
"surfactant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis that impacts aging and barth syndrome. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Apoptosis",
"Aging",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | C=C1CCC(=O)C2(C)Cc3occ(C)c3CC12 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a phosphorescent emitter that is phosphorescent and fluorescent. | CCc1oc2c(c1-c1ccccc1)N(C(C)C)c1ccccc1S2(=O)=O | [
"phosphorescent",
"fluorescent",
"phosphorescent emitter"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts barth syndrome, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts tangier disease and aging. | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is cancer treatment. | O=C(Oc1ccc(Cl)cc1)N1CCc2c([nH]c3c2CC(Cl)C=C3)C1c1ccc(OCCCCCCn2ccnc2)cc1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis that impacts diabetic heart disease and tangier disease. The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Apoptosis",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts tangier disease and diabetic heart disease. The molecule is a cholesterol translocation and a apoptosis that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Tangier disease",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, apoptosis, cholesterol translocation that impacts diabetic heart disease and tangier disease. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Apoptosis",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts diabetic heart disease, tangier disease, and barth syndrome. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts aging and non-alcoholic fatty liver disease. | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fluorescent, a organic electroluminescent device, and electroluminescent. | Cc1ccccc1N(c1ccc2cc3c(cc2c1)oc1c(C(C)C)c2oc4cc5cc(N(c6ccccc6C)c6ccc(C)c(C)c6C)ccc5cc4c2cc13)c1ccc(C)c(C)c1C | [
"fluorescent",
"organic electroluminescent device",
"electroluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and aging. | CCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase that impacts aging, tangier disease, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis, proton trap for oxidative phosphorylation that impacts diabetic heart disease. | CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCC | [
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Diabetic heart disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects both cervical cancer and breast cancer, and also impacts atherosclerosis and ulcerative colitis. | CCCCCC/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC | [
"Atherosclerosis",
"nutrient",
"Cervical cancer",
"Ulcerative colitis",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts barth syndrome and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Diabetic heart disease",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Aging",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a apoptosis that impacts diabetic heart disease, barth syndrome, and aging. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and tangier disease. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Barth syndrome",
"Aging",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the dielectric class of molecules. | CC1CCC(c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)C1 | [
"dielectric"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and barth syndrome. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, and diabetic heart disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCCCC | [
"Apoptosis",
"Tangier disease",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both pancreatitis and atherosclerosis. The molecule is a fat storage and a thyroxine treatment, impacting both metabolic syndrome and cardiovascular disease. | CCCC/C=C\CCCCCCCC(=O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"Pancreatitis",
"Atherosclerosis",
"nutrient",
"Fat storage",
"Metabolic syndrome",
"Thyroxine treatment",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to both the anti cancer and anti cancer agent classes of molecules. | CCC(O)C(C)C1OC1CC(C)C=CC=C(C)C1OC(=O)CC(O)CCC(C)(OC(C)=O)C(C2CNCCN2C(=O)O)C=CC1C | [
"anti cancer",
"anti cancer agent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti inflammatory. | COc1ccc(CNc2nc(NC3CCCCC3NC(=O)O)c3cc(C)ccc3n2)cc1 | [
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cftr modulator, ion channel modulator, and treatment of disorder compound. | CC(C)(C)N1CCC2(CC1)CC(=O)c1ccc(F)cc1O2 | [
"treatment of disorder",
"cftr modulator",
"ion channel modulator"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a kinase inhibitor and a cancer treatment. | CCCSNc1ccc(F)c(C(=O)c2c[nH]c3ncnc(NC4COC4)c23)c1F | [
"kinase inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts tangier disease, aging, and diabetic heart disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts barth syndrome and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Aging",
"Diabetic heart disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Barth syndrome",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts aging. The molecule is a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, diabetic heart disease, tangier disease, and barth syndrome. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Cholesterol translocation",
"Aging",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts barth syndrome and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and aging. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCC(C)C | [
"Barth syndrome",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Aging",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a serine protease inhibitor and a thrombosis treatment. | CC1CCCC(C)N1CCCCCN1C(=O)C(Cc2ccnc(N)n2)Cc2ccccc21 | [
"serine protease inhibitor",
"thrombosis treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, alzheimer's disease, non-alcoholic fatty liver disease, and parkinson's disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OCCN | [
"nutrient",
"Diabetes mellitus type 2",
"Alzheimer's Disease",
"Non-alcoholic fatty liver disease",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts seizure, diabetes mellitus, cardiovascular disease, and breast cancer. It has an effect on colorectal cancer, and impacts parkinson's disease, stomach cancer, and alzheimer's disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@@H]1COC(=O)CCC/C=C\C[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](OP(=O)(O)OC1)[C@H](O)[C@H](O)[C@@H](/C=C/[C@@H](O)CCCCC)C(=O)C[C@@H]2O | [
"Seizure",
"Diabetes mellitus",
"Cardiovascular disease",
"Breast cancer",
"Parkinson's disease",
"Stomach cancer",
"Colorectal cancer",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protein kinase inhibitor. | COC(=O)c1cc(Nc2ccccc2C)c(Nc2ccccc2C)cc1C(N)=O | [
"protein kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts non-alcoholic fatty liver disease, diabetes mellitus type 2, alzheimer's disease, and parkinson's disease. | CC/C=C/CC(O)/C=C/C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)COP(=O)(O)OCCN | [
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2",
"nutrient",
"Alzheimer's Disease",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti inflammatory class of molecules. | CCOC(=O)C(Cc1ccc(OCCO)cc1)Oc1ccc(C(C)C)cc1 | [
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts diabetic heart disease, non-alcoholic fatty liver disease, and tangier disease. The molecule is a apoptosis, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts barth syndrome and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, thyroxine treatment, energy storage that impacts atherosclerosis, pancreatitis, and cardiovascular disease. It impacts obesity, cancer, and metabolic syndrome. The molecule is a fat storage, inflammatory, energy source, membrane stabilizer. | CCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Atherosclerosis",
"nutrient",
"Pancreatitis",
"Thyroxine treatment",
"Cardiovascular disease",
"Energy storage",
"Obesity",
"Cancer",
"Metabolic syndrome",
"Fat storage",
"inflammatory",
"Energy source",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, membrane stabilizer, nutrient, inflammatory that impacts atherosclerosis and metabolic syndrome. It has an effect on cancer, impacting both pancreatitis and cardiovascular disease. The molecule is a energy storage, a fat storage, and a thyroxine treatment, and it impacts obesity. | CCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Energy source",
"Membrane stabilizer",
"nutrient",
"inflammatory",
"Atherosclerosis",
"Metabolic syndrome",
"Pancreatitis",
"Cancer",
"Cardiovascular disease",
"Obesity",
"Energy storage",
"Fat storage",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a gaba-gated chloride channel antagonist and a persistent organic pollutant. | CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc(=O)c2c([nH]1)c(CCC)nn2C | [
"GABA-gated chloride channel antagonist",
"persistent organic pollutant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, surfactant, membrane stabilizer, emulsifier, energy source, nutrient. | O=C1CC(c2ccc(O)cc2)Oc2c(O)ccc(O)c21 | [
"Energy storage",
"surfactant",
"Membrane stabilizer",
"Emulsifier",
"Energy source",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and aging. The molecule is a stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts barth syndrome and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCC(C)CC | [
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage and a inflammatory that impacts cancer, pancreatitis, metabolic syndrome, and cardiovascular disease. The molecule is a nutrient and membrane stabilizer, and it impacts obesity. The molecule is a energy source and a fat storage, it impacts atherosclerosis, and is thyroxine treatment. | CCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Cancer",
"Pancreatitis",
"Metabolic syndrome",
"Cardiovascular disease",
"Energy storage",
"inflammatory",
"nutrient",
"Obesity",
"Membrane stabilizer",
"Atherosclerosis",
"Energy source",
"Thyroxine treatment",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the cancer treatment class of molecules. | CC(C)(CN1CCOCC1)NCc1cccc(-c2ccc3ncnc(N)c3n2)c1.Cl | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts diabetic heart disease. The molecule is a stabilizing cytochrome oxidase that impacts barth syndrome, aging, tangier disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCC(C)C | [
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome",
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer and smooth, impacting both barth syndrome and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, food additive, proton trap for oxidative phosphorylation, nutritional supplement that impacts aging. The molecule is a apoptosis, a energy storage, and a cholesterol translocation, and it impacts diabetic heart disease. The molecule is a stabilizing mitochondrial structure, energy source, emulsifier, surfactant that impacts tangier disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Smooth",
"Membrane stabilizer",
"Stabilizing cytochrome oxidase",
"food additive",
"Aging",
"Proton trap for oxidative phosphorylation",
"Nutritional supplement",
"Apoptosis",
"Diabetic heart disease",
"Energy storage",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Energy source",
"Emulsifier",
"surfactant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti viral. | COc1cc(C)c(S(=O)(=O)N(C(Cc2ccccc2)C(=O)O)C(C)c2c(Oc3ccc(Cl)cc3Cl)n[nH]c2C(F)(F)F)c(C)c1C | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts barth syndrome, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts aging and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Aging",
"Tangier disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor, a mps1 inhibitor, and cancer treatment. | Nc1nc2cnc(-c3ccc(NC(=O)Cc4ccccc4)cc3)cn2n1 | [
"kinase inhibitor",
"mps1 inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, fat storage, inflammatory that belongs to the thyroxine treatment class of molecules and impacts both pancreatitis and cancer. The molecule is a nutrient and energy storage, and it impacts metabolic syndrome. The molecule is a energy source that impacts obesity, cardiovascular disease, and atherosclerosis. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC | [
"Membrane stabilizer",
"Fat storage",
"Pancreatitis",
"inflammatory",
"Thyroxine treatment",
"Cancer",
"nutrient",
"Energy storage",
"Metabolic syndrome",
"Obesity",
"Energy source",
"Cardiovascular disease",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the proliferative disorder treatment class of molecules. | CN(c1nc(-c2ccnc(N(C3CCNCC3)C3CC3)c2)nc2cncc(C3CC3)c12)C1CCNCC1 | [
"proliferative disorder treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hsp90 inhibitor and belongs to the cancer treatment class of molecules. | c1nc2c3cocc3ncn2n1 | [
"hsp90 inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a ace inhibitor. | CC(C)CC(NC(=O)C(CS)Cc1ccccc1)C(N)=O | [
"ace inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts diabetic heart disease, non-alcoholic fatty liver disease, and tangier disease. The molecule is a cholesterol translocation, apoptosis, proton trap for oxidative phosphorylation that impacts aging and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Cholesterol translocation",
"Apoptosis",
"Aging",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both cardiovascular disease and atherosclerosis. The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting both metabolic syndrome and pancreatitis. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC | [
"nutrient",
"Cardiovascular disease",
"Atherosclerosis",
"Thyroxine treatment",
"Metabolic syndrome",
"Fat storage",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and nutrient, and it impacts cardiovascular disease. The molecule is a member of the thyroxine treatment class and affects metabolic syndrome, pancreatitis, and atherosclerosis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCCCC/C=C\CCCCCC | [
"Fat storage",
"nutrient",
"Cardiovascular disease",
"Metabolic syndrome",
"Pancreatitis",
"Atherosclerosis",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts cancer treatment. | CCC(=C(c1ccc(C=CC(=O)NS(=O)(=O)c2ccncc2)cc1)c1ccc2nc[nH]c2c1)c1ccc(F)cc1Cl | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to both the anti viral and anti viral agent classes of molecules. | C=CC1CC1(NC(=O)C1CC(Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)CC(CC1CCCC1)C(=O)N1CCCCC1)C(=O)NS(=O)(=O)C1CC1 | [
"anti viral",
"anti viral agent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nampt inhibitor, a rock inhibitor, and a cancer treatment. | O=C(Nc1ccc(OC2CCNCC2)nc1)n1cc2ccccc2c1 | [
"nampt inhibitor",
"rock inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis that impacts aging and tangier disease. The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts diabetic heart disease, non-alcoholic fatty liver disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)CC | [
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Aging",
"Apoptosis",
"Tangier disease",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts metabolic syndrome, atherosclerosis, obesity, pancreatitis, and cancer. The molecule is a fat storage, a energy storage, and a membrane stabilizer. The molecule is a inflammatory and a energy source, it impacts cardiovascular disease, and is thyroxine treatment. | CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Metabolic syndrome",
"Atherosclerosis",
"Obesity",
"nutrient",
"Pancreatitis",
"Cancer",
"Fat storage",
"Energy storage",
"Membrane stabilizer",
"Cardiovascular disease",
"inflammatory",
"Energy source",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the thyroxine treatment class and affects both pancreatitis and atherosclerosis. The molecule is a nutrient and a fat storage, impacting both cardiovascular disease and metabolic syndrome. | CCCCC/C=C\C/C=C\CCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Thyroxine treatment",
"Pancreatitis",
"Atherosclerosis",
"Cardiovascular disease",
"nutrient",
"Fat storage",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a mps1 inhibitor and is cancer treatment. | CNC(=O)Nc1ccc(-c2cnc3c(NCc4ccccc4F)nc4ccc(F)cc4n23)cc1 | [
"cancer treatment",
"mps1 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a electronic device and is light-emitting. | CCCn1c(-c2ccc(-c3cccc4c3sc3ccccc34)cc2)nc2ccccc21 | [
"light-emitting",
"electronic device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
When heated to decomposition it emits toxic vapors of nitrogen oxides and hydrogen chloride. The molecule has Aromatic odor. | CCOCN(C(=O)CCl)c1c(C)cccc1CC | [
"Decomposition_evaluation",
"Odor_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts aging and tangier disease. The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, diabetic heart disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Aging",
"Tangier disease",
"Apoptosis",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, energy storage, fat storage, membrane stabilizer that impacts metabolic syndrome and cardiovascular disease. The molecule is a energy source and belongs to the thyroxine treatment class of molecules, impacting pancreatitis. The molecule is a nutrient that affects cancer by impacting both atherosclerosis and obesity. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"Metabolic syndrome",
"inflammatory",
"Cardiovascular disease",
"Energy storage",
"Fat storage",
"Membrane stabilizer",
"Energy source",
"Pancreatitis",
"Thyroxine treatment",
"Atherosclerosis",
"Cancer",
"nutrient",
"Obesity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts tangier disease and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It influences both stomach cancer and colorectal cancer, as well as affecting seizure and breast cancer. It impacts alzheimer's disease, diabetes mellitus, parkinson's disease, and cardiovascular disease. | CCCCC/C=C\C[C@@H](O)/C=C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC | [
"Seizure",
"Stomach cancer",
"Breast cancer",
"Colorectal cancer",
"Alzheimer's Disease",
"Diabetes mellitus",
"Parkinson's disease",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts pancreatitis, metabolic syndrome, and thyroxine treatment. The molecule is a fat storage and a nutrient, impacting both atherosclerosis and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COC(=O)CCCCCCCCCCCCCC | [
"Pancreatitis",
"Metabolic syndrome",
"Thyroxine treatment",
"Atherosclerosis",
"Fat storage",
"Cardiovascular disease",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure that impacts aging, barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis, proton trap for oxidative phosphorylation that impacts tangier disease. | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"Aging",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a lpxc inhibitor, a anti microbial, and anti bacterial. | COC(=O)c1ccc(C#CC=CCl)cc1 | [
"lpxc inhibitor",
"anti microbial",
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase that impacts diabetic heart disease and tangier disease. | CCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a lpa antagonist. | Cc1nc(-c2nnn(C)c2CNC(=O)OC2CCCC2)ccc1OC1CCCC(C=O)(CO)C1 | [
"lpa antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts seizure, diabetes mellitus, and cardiovascular disease. It has an effect on stomach cancer, and impacts colorectal cancer, parkinson's disease, and alzheimer's disease. | CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\[C@H](O)CCCC | [
"Seizure",
"Diabetes mellitus",
"Cardiovascular disease",
"Breast cancer",
"Stomach cancer",
"Colorectal cancer",
"Parkinson's disease",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | O=C(/C=C\c1ccc(O)c(O)c1)Oc1ccc(-c2cc(=O)c3c(O)cc(OC4OC(CO)C(O)C(O)C4O)cc3o2)cc1 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, apoptosis, cholesterol translocation that impacts barth syndrome and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Apoptosis",
"Cholesterol translocation",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti viral class of molecules. | Cc1cc(C)cc([Se]c2c(C(C)C)c(=O)[nH]c(=O)n2COCCO)c1 | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts aging, non-alcoholic fatty liver disease, and tangier disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Apoptosis",
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, parkinson's disease, alzheimer's disease, and non-alcoholic fatty liver disease. | CCCCC/C=C\C[C@H](O)/C=C/C=C/C=C\[C@H](O)CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCc1oc(CCCCC)c(C)c1C)COP(=O)(O)OCCN | [
"Diabetes mellitus type 2",
"Parkinson's disease",
"nutrient",
"Alzheimer's Disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease and aging. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts barth syndrome, tangier disease, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Aging",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Tangier disease",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis that impacts tangier disease, aging, barth syndrome, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Tangier disease",
"Apoptosis",
"Aging",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and barth syndrome. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and aging. | CCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on colorectal cancer, and impacts stomach cancer, breast cancer, and cardiovascular disease. It impacts seizure, diabetes mellitus, alzheimer's disease, and parkinson's disease. | CC/C=C\CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C/C=C/C(O)C/C=C\CC | [
"Stomach cancer",
"Colorectal cancer",
"Breast cancer",
"Cardiovascular disease",
"Seizure",
"Diabetes mellitus",
"Alzheimer's Disease",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase, impacting both aging and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, energy source, membrane stabilizer, emulsifier that impacts tangier disease. The molecule is a nutritional supplement, a energy storage, a surfactant, and smooth. The molecule is a apoptosis, cholesterol translocation, food additive that impacts barth syndrome and diabetic heart disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)C | [
"Aging",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Energy source",
"Membrane stabilizer",
"Emulsifier",
"Tangier disease",
"Nutritional supplement",
"Smooth",
"Energy storage",
"surfactant",
"Barth syndrome",
"Apoptosis",
"Cholesterol translocation",
"food additive",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts tangier disease, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts aging and barth syndrome. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C=C/CCCCCC | [
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Aging",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, a fat storage, and a energy storage that impacts both metabolic syndrome and pancreatitis, and is thyroxine treatment. The molecule is a energy source that impacts both obesity and atherosclerosis. The molecule is a nutrient and a inflammatory, impacting both cancer and cardiovascular disease. | CCC(C)CCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Metabolic syndrome",
"Membrane stabilizer",
"Fat storage",
"Thyroxine treatment",
"Energy storage",
"Pancreatitis",
"Energy source",
"Obesity",
"Atherosclerosis",
"nutrient",
"Cancer",
"inflammatory",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure that impacts diabetic heart disease, tangier disease, aging, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts barth syndrome. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts diabetic heart disease and tangier disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Cholesterol translocation",
"Diabetic heart disease",
"Apoptosis",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts barth syndrome and aging. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a thyroxine treatment and a nutrient that impacts atherosclerosis, cardiovascular disease, metabolic syndrome, and obesity. The molecule is a energy storage, a inflammatory, and a energy source. The molecule is a fat storage and a membrane stabilizer, with effects on cancer and impacts on pancreatitis. | CCC(C)CCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Thyroxine treatment",
"Atherosclerosis",
"Cardiovascular disease",
"nutrient",
"Metabolic syndrome",
"Obesity",
"Energy storage",
"inflammatory",
"Energy source",
"Cancer",
"Pancreatitis",
"Fat storage",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, parkinson's disease, non-alcoholic fatty liver disease, and alzheimer's disease. | CCCCC/C=C\C/C=C\C/C=C\CC1OC1CCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"nutrient",
"Diabetes mellitus type 2",
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, energy source, thyroxine treatment, nutrient that has an effect on cancer and impacts pancreatitis. The molecule is a energy storage that impacts both obesity and cardiovascular disease. The molecule is a inflammatory and a membrane stabilizer, impacting both atherosclerosis and metabolic syndrome. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCC | [
"Fat storage",
"Energy source",
"Cancer",
"Pancreatitis",
"Thyroxine treatment",
"nutrient",
"Obesity",
"Cardiovascular disease",
"Energy storage",
"inflammatory",
"Membrane stabilizer",
"Atherosclerosis",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts aging, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a apoptosis that impacts non-alcoholic fatty liver disease, tangier disease, and barth syndrome. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts aging and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome",
"Aging",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, a stabilizing mitochondrial structure, and a nutritional supplement, and it impacts tangier disease. The molecule is a apoptosis, food additive, surfactant, cholesterol translocation that impacts barth syndrome. The molecule is a proton trap for oxidative phosphorylation and a energy source, impacting both non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a membrane stabilizer, a stabilizing cytochrome oxidase, and a emulsifier, it impacts aging and is smooth. | CCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Energy storage",
"Stabilizing mitochondrial structure",
"Nutritional supplement",
"Tangier disease",
"Apoptosis",
"food additive",
"surfactant",
"Cholesterol translocation",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Energy source",
"Membrane stabilizer",
"Stabilizing cytochrome oxidase",
"Aging",
"Emulsifier",
"Smooth"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and membrane stabilizer, affecting cancer, and impacting cardiovascular disease, atherosclerosis, and pancreatitis. The molecule is a thyroxine treatment, a fat storage, and a energy source. The molecule is a energy storage and a inflammatory, impacting both metabolic syndrome and obesity. | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"nutrient",
"Cardiovascular disease",
"Atherosclerosis",
"Membrane stabilizer",
"Cancer",
"Pancreatitis",
"Thyroxine treatment",
"Fat storage",
"Energy source",
"Metabolic syndrome",
"Energy storage",
"Obesity",
"inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a trpm8 antagonist and belongs to the inflammatory treatment class of molecules, with the characteristic of being pain treatment. | O=C(CN1C(=O)NC2(CCC(F)(F)CC2)C1=O)c1ccc(OCc2ccccn2)cc1 | [
"inflammatory treatment",
"trpm8 antagonist",
"pain treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a cholesterol translocation and a apoptosis that impacts tangier disease, barth syndrome, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation",
"Apoptosis",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both cardiovascular disease and pancreatitis. The molecule is a fat storage and a thyroxine treatment, impacting both atherosclerosis and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC(COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCC | [
"nutrient",
"Cardiovascular disease",
"Pancreatitis",
"Fat storage",
"Atherosclerosis",
"Thyroxine treatment",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, apoptosis, proton trap for oxidative phosphorylation that impacts diabetic heart disease and tangier disease. The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Tangier disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Aging",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits